Hemab Therapeutics Holdings, Inc.
COAGNasdaqCIK 2114044HealthcareFiscal year ends Dec 31
Reports and events: 12 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2416:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-401010 |
| 2026-08-1116:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344533 |
| 2026-08-1107:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343421 |
| 2026-05-2116:02 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-234386 |
| 2026-05-2107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-233375 |
| 2026-05-1116:43 ET | SCHEDULE 13D | Ownership report, active investor | 0001193125-26-216973 |
| 2026-05-1116:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-216699 |
| 2026-05-0416:09 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-203988 |
| 2026-04-3006:39 ET | S-1/A | Registration statement, amended | 0001193125-26-193885 |
| 2026-04-2816:08 ET | S-1/A | Registration statement, amended | 0001193125-26-186964 |
| 2026-04-2707:09 ET | S-1/A | Registration statement, amended | 0001193125-26-178809 |
| 2026-04-1016:41 ET | S-1 | Registration statement | 0001193125-26-151378 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.